ロード中...
Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma
AIMS: Medicare patients with metastatic or surgically unresectable urothelial carcinoma (mUC) often receive platinum-based chemotherapy as first line of therapy (LOT) but invariably progress, requiring additional LOTs and healthcare resource use (HCRU). To better understand the evolving mUC treatmen...
保存先:
| 出版年: | J Med Econ |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7384456/ https://ncbi.nlm.nih.gov/pubmed/30836812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13696998.2019.1591424 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|